Recursion Pharmaceuticals, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Material agreementSep 21 →InsidersNo open-market buys. 5 insiders sold $8.0M, all 31 sales on a 10b5-1 plan.→HoldersBlackRock 9.4%ARK 7.7%State Street 6.5%→Financing →PeersClosest companies: SDGR, EIKN, GLUE→
From the filings
Figures
- Revenue
- $54.9Mlast 12 months
- Net income
- −$518.9Mlast 12 months
- Operating cash flow
- −$321.0Mlast 12 months
- Cash and equivalents
- $545.7Mat the last balance sheet
- Total debt
- $14.2Mat the last balance sheet
- Shares outstanding
- 534.1M shareson issue